Chronic beryllium disease

Clinical Pulmonary Medicine

Volumn 10, Issue 2, 2003, Pages 72-79

  Culver, Daniel A ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Berylliosis; Chronic beryllium disease; Granuloma; Human leukocyte antigen; Occupational disease

Indexed keywords

CD4 ANTIGEN; CORTICOSTEROID; GAMMA INTERFERON; HLA ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BERYLLIOSIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; HELPER CELL; HUMAN; HYPERSENSITIVITY REACTION; HYPOXEMIA; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; LUNG GRANULOMA; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MUCOSA INFLAMMATION; OCCUPATIONAL ACCIDENT; OCCUPATIONAL EXPOSURE; PHENOTYPE; RISK FACTOR; SARCOIDOSIS; SYMPTOMATOLOGY; T LYMPHOCYTE;

EID: 0037340010     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000051418.18963.cb     Document Type: Article

References (65)

1. Van Ordstarnd HS, Hughes R, Carmody MG. Chemical pneumonia in workers extracting beryllium oxide. Report of three cases. Cleve Clin Q. 1943;10:10.
2. Eisenbud M. Origin of the standards for control of beryllium disease (1947-1949). Environ Res. 1982;27:79-88.
3. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol. 1946;28:197-211.
4. Kriebel D, Brain JD, Sprince NL, et al. The pulmonary toxicity of beryllium. Am Rev Respir Dis. 1988;137:464-473.
5. Newman LS. Immunology, genetics and epidemiology of beryllium disease. Chest. 1996;109:40S-43S.
6. Eisenbud M, Lisson J. Epidemiological aspects of beryllium-induced nonmalignant lung disease: a 30-year update. J Occup Med. 1983;25:196-202.
7. Cullen MR, Kominsky JR, Rossman MD, et al. Chronic beryllium disease in a precious metal refinery. Am Rev Respir Dis. 1987;135:201-208.
8. Kotloff RM, Richman PS, Greenacre JK, et al. Chronic beryllium disease in a dental laboratory. Am Rev Respir Dis. 1993;147:205-207.
9. Kreiss K, Mroz MM, Zhen B, et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med. 1997;54:605-612.
10. Kreiss K, Wasserman S, Mroz MM, et al. Beryllium disease screening in the ceramics industry. J Occup Med. 1993;35:267-274.
11. 3. Am J Indust Med. 1996;30:16-25.
12. Kreiss K, Newman LS, Mroz MM, et al. Screening blood test identifies subclinical beryllium disease. J Occup Med. 1989;31:603-608.
13. Markham TN. Screening for chronic beryllium disease using beryllium specific lymphocyte proliferation testing. Int Arch Occup Environ Health. 1996;68:405-407.
14. Newman LS, Mroz MM, Maier LA, et al. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med. 2001;43:231-237.
15. Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993;148:985-991.
16. Samuel G, Wiedemann HP, Dweik RA. Effect of smoking and race on the development of chronic beryllium disease in sensitized individuals. Chest. 2001;120:185S-186S.
17. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis. 1992;145:1212-1214.
18. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001;74:167-176.
19. Kent MS, Robins TG, Madl AK. Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. Appl Occup Environ Hygenie. 2001;16:539-558.
20. Paustenbach DJ, Madl AK, Greene JF. Identifying an appropriate occupational exposure limit (OEL) for beryllium: data gaps and current research initiatives. Appl Occup Environ Hygenie. 2001;16:527-538.
21. Saltini C, Winestock K, Kirby M, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989;320:1103-1109.
22. Tinkle SS, Schwitters PW, Newman LS. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ Health Perspect. 1996;104, Suppl 5:969-971.
23. Maier LA, Sawyer RT, Tinkle SS, et al. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Resp J. 2001;17:403-415.
24. Tinkle SS, Kittle LA, Schumacher BA, et al. Beryllium induces IL-2 and IFN-γ in berylliosis. J Immunol. 1997;158:518-526.
25. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor-α in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731-740.
26. Bost TW, Riches DWH, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am J Respir Cell Mol Biol. 1994;10:506-513.
27. Tinkle SS, Newman LS. Beryllium-stimulated release of tumor necrosis factor-α, interleu-kin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med. 1997;156:1884-1891.
28. Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. J Immunol. 1999;163:2747-2753.
29. Maier LA, Sawyer RT, Bauer RA, et al. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med. 2001;164:1192-1199.
30. Barna BP, Dweik RA, Farver CF, et al. Nitric oxide attenuates beryllium-induced IFNγ responses in Chronic Beryllium Disease: evidence for mechanisms independent of IL-18. Clinical Immunology. 2002;103:169-175.
31. Hogaboam CM, Chensue SW, Steinhauser ML, et al. Alteration of the cytokine phenotype in an experimental lung granuloma model by inhibiting nitric oxide. J Immunol. 1997;159:5585-5593.
32. Dweik RA, Laskowski D, Erzurum SC. High levels of nitric oxide (NO) in exhaled breath in patients with chronic beryllium disease. Am J Respir Crit Care Med. 2000;161:A731.
33. Ozkan M, Dweik RA. Nitric oxide in reactive airway disease. Clin Pulm Med. 2001;8:199-206.
34. Saltini C, Amicosante M. Beryllium disease. Am J Med Sci. 2001;321:89-98.
35. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science. 1993;262:242-244.
36. Richeldi L, Kreiss K, Mroz MM, et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997;32:337-340.
37. Wang Z, White PS, Petrovic M, et al. Differential susceptibility to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999;163:1647-1653.
38. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Resp J. 2001;18:677-684.
39. Rossman MD, Stubbs J, Lee CW, et al. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium sensitivity. Am J Respir Crit Care Med. 2002;165:788-794.
40. Lombardi G, Germain C, Uren J, et al. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol. 2001;166:3549-3555.
41. Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001;100:4-14.
42. Newman LS, Kreiss K, King TE, et al. Pathologic and immunologic alterations in early stages of beryllium disease. Am Rev Respir Dis. 1989;139:1479-1486.
43. Saber W, Dweik RA. A 61 year old male with dyspnea and ground glass infiltrates on CT (Chronic Beryllium Disease). Cleve Clin J Med 2000;67:791-800.
44. Dweik RA. Berylliosis. In: eMedicine (http://www.emedicine.com). Accessed 3 February 2003). Plantz SH and Zevitz ME, eds. Volume 2, 2001.
45. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease: long-term follow-up of sixty cases and selective review of the literature. Am J Med. 1969;46:545-561.
46. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis. 1993;148:661-666.
47. Andrews JL, Kazemi H, Hardy HL. Pattern of lung dysfunction in chronic beryllium disease. Am Rev Respir Dis. 1969;100:791-800.
48. Aronchick JM, Rossman MD, Miller WT. Chronic beryllium disease: diagnosis, radiographic findings, and correlation with pulmonary function tests. Radiology. 1987;163:677-682.
49. Newman LS, Buschman DL, Newell JD, et al. Beryllium disease: assessment with CT. Radiology. 1994;190:835-840.
50. Daniloff EM, Lynch DA, Bucher Bartelson B, et al. Observer variation and relationship. of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med. 1997;155:2047-2056.
51. Newman LS, Bobka C, Schumacher, et al. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med. 1994;150:135-142.
52. Freiman DG, Hardy HL. Beryllium disease: the relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Hum Pathol. 1970;1:25-44.
53. Hanifin JM, Epstein WL, Cline MJ. In vitro studies of granulomatous hypersensitivity to beryllium. J Invest Dermatol. 1970;55:284-288.
54. Epstein PE, Dauber JH, Rossman MD, et al. Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonitis. Ann Intern Med. 1982;97:213-216.
55. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium: a test for chronic beryllium disease. Ann Intern Med. 1988;108:687-693.
56. Mroz MM, Kreiss K, Lezotte DC, et al. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol. 1991;88:54-60.
57. Stokes RF, Rossman MD. Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med. 1991;33:23-28.
58. Deubner DC, Goodman M, Iannuzzi J. Variability, predictive value, an uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hygiene. 2001;16:521-526.
59. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect. 1996;104(Suppl 5):953-956.
60. Saber WS, Ozkan M, Lee JC, Wiedemann HP, Dweik RA. Pulmonary function testing in patients with chronic beryllium disease. Chest. 2000;118:253S.
61. Barna BP, Deodhar SD, Chiang T, et al. Experimental beryllium-induced lung disease: I. Differences in immunologic responses to beryllium compounds in strains 2 and 13 guinea pigs. Int Arch Allergy Appl Immunol. 1984;73:42-48.
62. Votto JJ, Barton RW, Gionfriddo MA, et al. A model of pulmonary granulomata induced by beryllium sulfate in the rat. Sarcoidosis. 1987;4:71-76.
63. Sprince NL, Kanarek DJ, Weber AL, et al. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis. 1978;117:1011-1017.
64. Munck A, Mendel DB, Smith LI, et al. Glucocorticoid receptors and actions. Am Rev Resp Dis. 1990;141:S2-S10.
65. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-74.